Total Payments
$46,071
2024 Payments
$24,502
Companies
37
Transactions
1,054
Medicare Patients
1,741
Medicare Billing
$170,222
Payment Breakdown by Category
Other$22,869 (49.6%)
Food & Beverage$19,203 (41.7%)
Travel$3,478 (7.5%)
Education$521.46 (1.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $22,869 | 13 | 49.6% |
| Food and Beverage | $19,203 | 1,009 | 41.7% |
| Travel and Lodging | $3,478 | 5 | 7.5% |
| Education | $521.46 | 27 | 1.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $29,493 | 127 | $0 (2024) |
| Novo Nordisk Inc | $3,618 | 203 | $0 (2024) |
| GlaxoSmithKline, LLC. | $1,748 | 116 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $1,513 | 57 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $1,418 | 40 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $1,111 | 47 | $0 (2020) |
| Lilly USA, LLC | $1,033 | 90 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $934.83 | 45 | $0 (2019) |
| PFIZER INC. | $785.17 | 43 | $0 (2020) |
| Merck Sharp & Dohme Corporation | $700.18 | 52 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $24,502 | 72 | Amgen Inc. ($23,444) |
| 2023 | $5,139 | 57 | Amgen Inc. ($4,224) |
| 2022 | $811.47 | 19 | Novo Nordisk Inc ($309.03) |
| 2021 | $1,377 | 40 | Novo Nordisk Inc ($421.67) |
| 2020 | $866.73 | 55 | GlaxoSmithKline, LLC. ($196.39) |
| 2019 | $4,644 | 302 | Amgen Inc. ($686.41) |
| 2018 | $4,531 | 243 | Novo Nordisk Inc ($641.13) |
| 2017 | $4,200 | 266 | Novo Nordisk Inc ($816.90) |
All Payment Transactions
1,054 individual payment records from CMS Open Payments — Page 1 of 43
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $6.56 | General |
| Category: RESPIRATORY | ||||||
| 11/22/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $5.72 | General |
| Category: RESPIRATORY | ||||||
| 11/20/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $18.34 | General |
| Category: Respiratory | ||||||
| 11/20/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $13.73 | General |
| Category: Diabetes | ||||||
| 10/30/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $14.58 | General |
| Category: Inflammation | ||||||
| 09/25/2024 | SANOFI-AVENTIS U.S. LLC | TZIELD (Biological) | Food and Beverage | In-kind items and services | $89.44 | General |
| Category: Endocrine & Metabolic Diseases | ||||||
| 09/24/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $16.96 | General |
| Category: Respiratory | ||||||
| 09/24/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $11.52 | General |
| Category: Inflammation | ||||||
| 09/12/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Food and Beverage | In-kind items and services | $3.29 | General |
| Category: Obesity | ||||||
| 09/12/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Food and Beverage | In-kind items and services | $1.83 | General |
| Category: Obesity | ||||||
| 09/10/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Food and Beverage | In-kind items and services | $124.80 | General |
| Category: RESPIRATORY | ||||||
| 09/09/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $7.87 | General |
| Category: Inflammation | ||||||
| 09/04/2024 | Novo Nordisk Inc | Wegovy (Drug) | Food and Beverage | In-kind items and services | $22.37 | General |
| Category: Obesity | ||||||
| 08/23/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $17.42 | General |
| Category: Diabetes | ||||||
| 08/23/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $1.06 | General |
| Category: Diabetes | ||||||
| 08/21/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $16.56 | General |
| Category: RESPIRATORY | ||||||
| 08/07/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $7.22 | General |
| Category: Diabetes | ||||||
| 07/31/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $10.13 | General |
| Category: Inflammation | ||||||
| 07/24/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $7.26 | General |
| Category: RESPIRATORY | ||||||
| 07/24/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $4.34 | General |
| Category: RESPIRATORY | ||||||
| 07/23/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $16.96 | General |
| Category: Respiratory | ||||||
| 07/17/2024 | Amgen Inc. | Repatha (Biological) | Travel and Lodging | In-kind items and services | $934.80 | General |
| Category: Cardiology | ||||||
| 07/16/2024 | Amgen Inc. | Repatha (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,800.00 | General |
| Category: Cardiology | ||||||
| 07/16/2024 | Amgen Inc. | Repatha (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $467.00 | General |
| Category: Cardiology | ||||||
| 07/11/2024 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $10.50 | General |
| Category: Cardiology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 16 | 562 | 1,891 | $163,867 | $74,531 |
| 2022 | 12 | 448 | 568 | $84,058 | $39,940 |
| 2021 | 9 | 318 | 426 | $57,982 | $27,637 |
| 2020 | 12 | 413 | 590 | $61,775 | $28,114 |
Total Patients
1,741
Total Services
3,475
Medicare Billing
$170,222
Procedure Codes
49
All Medicare Procedures & Services
49 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 12 | 1,200 | $43,200 | $22,085 | 51.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 110 | 180 | $34,920 | $14,639 | 41.9% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 85 | 85 | $22,950 | $10,734 | 46.8% |
| 90677 | Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | Office | 2023 | 17 | 17 | $6,052 | $4,770 | 78.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 25 | 34 | $9,112 | $4,677 | 51.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 61 | 76 | $9,348 | $4,567 | 48.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 32 | 38 | $8,246 | $2,356 | 28.6% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 29 | 30 | $3,300 | $2,148 | 65.1% |
| G0402 | Initial preventive physical examination; face-to-face visit, services limited to new beneficiary during the first 12 months of medicare enrollment | Office | 2023 | 13 | 13 | $3,770 | $2,113 | 56.0% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 21 | 21 | $8,820 | $2,056 | 23.3% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 23 | 23 | $4,968 | $1,453 | 29.2% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 33 | 34 | $1,292 | $1,090 | 84.3% |
| G0009 | Administration of pneumococcal vaccine | Office | 2023 | 26 | 26 | $988.00 | $833.30 | 84.3% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 22 | 49 | $3,430 | $513.52 | 15.0% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 31 | 42 | $2,436 | $399.84 | 16.4% |
| 93005 | Routine electrocardiogram (ecg) using at least 12 leads with tracing | Office | 2023 | 22 | 23 | $1,035 | $96.20 | 9.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 94 | 157 | $30,458 | $13,550 | 44.5% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 61 | 61 | $16,470 | $7,811 | 47.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 68 | 91 | $11,769 | $5,165 | 43.9% |
| 90677 | Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | Office | 2022 | 17 | 17 | $6,052 | $4,727 | 78.1% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2022 | 42 | 42 | $4,620 | $2,868 | 62.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 12 | 13 | $3,484 | $1,850 | 53.1% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 48 | 48 | $1,824 | $1,493 | 81.8% |
| G0009 | Administration of pneumococcal vaccine | Office | 2022 | 33 | 33 | $1,254 | $1,030 | 82.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 11 | 11 | $2,387 | $630.56 | 26.4% |
About Dr. Nathan Kakish, MD
Dr. Nathan Kakish, MD is a Pediatrics healthcare provider based in West Dundee, Illinois. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/04/2006. The National Provider Identifier (NPI) number assigned to this provider is 1518975309.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Nathan Kakish, MD has received a total of $46,071 in payments from pharmaceutical and medical device companies, with $24,502 received in 2024. These payments were reported across 1,054 transactions from 37 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($22,869).
As a Medicare-enrolled provider, Kakish has provided services to 1,741 Medicare beneficiaries, totaling 3,475 services with total Medicare billing of $170,222. Data is available for 4 years (2020–2023), covering 49 distinct procedure/service records.
Ad
Practice Information
- Specialty Pediatrics
- Other Specialties Internal Medicine
- Location West Dundee, IL
- Active Since 08/04/2006
- Last Updated 09/14/2020
- Taxonomy Code 208000000X
- Entity Type Individual
- NPI Number 1518975309
Products in Payments
- Repatha (Biological) $28,002
- ENTRESTO (Drug) $1,111
- FARXIGA (Drug) $803.62
- Ozempic (Drug) $786.66
- TRELEGY ELLIPTA (Drug) $755.02
- INVOKANA (Drug) $659.26
- Aimovig (Biological) $562.23
- Vascepa (Drug) $559.17
- Otezla (Drug) $557.87
- Tresiba (Drug) $551.10
- Victoza (Drug) $516.11
- Saxenda (Drug) $483.44
- JANUVIA (Drug) $444.29
- CHANTIX (Drug) $425.87
- TRULICITY (Drug) $401.58
- TOUJEO (Drug) $339.33
- ANORO (Drug) $330.85
- Wegovy (Drug) $314.27
- SYMBICORT (Drug) $271.09
- Prolia (Biological) $270.49
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.